SummaryRMgm-255
|
Successful modification | The gene/parasite could not be changed/generated by the genetic modification. |
The following genetic modifications were attempted | Gene disruption |
Number of attempts to introduce the genetic modification | 3 |
Reference (PubMed-PMID number) | Not published (yet) |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA 507cl1 (RMgm-7) |
Other information parent line | P.berghei ANKA 507cl1 (RMgm-7) is a reference ANKA mutant line which expresses GFP under control of a constitutive promoter (PubMed: PMID: 16242190). |
top of page | |
Attempts to generate the mutant parasite were performed by | |
Name PI/Researcher | E. Laurentino, C.J. Janse |
Name Group/Department | Leiden Malaria Research Group |
Name Institute | Leiden University Medical Center |
City | Leiden |
Country | The Netherlands |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1232200 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0517400 | ||||||||||||||||||||||||
Gene product | FACT complex subunit SPT16, putative | ||||||||||||||||||||||||
Gene product: Alternative name | FACT-L; FACT | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence |
AATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTT
| ||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Partial | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | PB000119.00.0 reads 3231 bp (PlasmoDB). The selectable marker was inserted between bp positions 1090 and 2502, replacing everything in between. | ||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | The unsuccessful ttempts to disrupt the fact-l gene in P. berghei indicates an essential role of FACT-L for blood stage development/multiplication. See also RMgm-652, RMgm-653 and RMgm-654 for mutants in which the promoter of fact-l is replaced by an 'asexual blood stage specific’ promoter that is silent in gametocytes (the promoter of PBANKA_140060). Disruption experiments were performed in the Leiden Malaria Research Group (Exp. 902, 917; pl1230) An additional attempt to disrupt the gene was performed using a different plasmid targeting a bigger part of the gene (double cross-over integration; exp. 1147; pl1147). Primers used to amplify the target sequences are L3576 (SacII): gcCCGCGGATGCAATCCTTATTAGTG; L3576 (StuI): gcAGGCCTCATCTGATTTAGATCTAAG; L3577 (XhoI): cCTCGAGCTAGAAAGAGTACATCATGG; L3578 (EcoRV): gcGATATCGCGTTCATTTCATATATAAC. The selectable marker was inserted between bp positions 519 and 2742 of the PB000119.00.0 ORF, replacing everything in between. | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |